What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?

Routine monitoring of triglyceride levels is not considered standard practice during pegaspargase therapy. Although hypertriglyceridemia is a common side effect of asparaginase treatment, it typically has no significant clinical impact on management decisions or future use of asparaginase. The condition is usually self-limited, and available experiences have not demonstrated a correlation between hypertriglyceridemia and an increased risk of pancreatitis during asparaginase therapy. In cases of ...